Home › Trial NCT07361874
IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion
- Trial IDNCT07361874
- StatusRecruiting
- PhaseN/A
- Study typeInterventional
- SponsorUniversity of Texas Southwestern Medical Center
- Enrollment75
- Start date2026-03-05
- ConditionsMild Autonomous Cortisol Secretion (MACS) · Autonomous Cortisol Secretion (ACS) · Subclinical Cushing's · Mild Autonomous Cortisol Excess
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.